The global spinal cord stimulation devices market size was valued at USD 1.83 billion in 2018 and is anticipated to expand at a CAGR of 8.7% during the forecast period. A spinal cord stimulation device consists of a thin wire, which carries out current from the pulse generator to the nerve fibers of the spinal cord. The rise in a number of patients suffering from the failed back syndrome, chronic pain, and Complex Regional Pain Syndrome (CRPS) is the key factor boosting the market growth.
CRPS is a condition of chronic pain that affects one limb (hand, arm, leg, or foot), and occurs after an injury. It is categorized into two types: CRPS-I and CRPS-II. Individuals who don’t have confirmed nerve injury are classified in CRPS-I and those who have confirmed nerve associated injury are classified in CRPS-II.
According to the National Institute of Neurological Disorders and Stroke (NINDS), symptoms of CRPS are most commonly found in women and can occur at any age. In 90.0% of cases, CRPS occurs due to trauma and injury. Thus, the increasing number of patients suffering from chronic pain drives the market growth.
It is used for the treatment of chronic pain by modifying and blocking the pain signals before they reach to the brain. According to the National Center for Biotechnology Information (NCBI), the treatment of spinal cord stimulation depends on electrical stimulation on the dorsal surface of the spinal cord that blocks the neuropathic pain.
Rechargeable device is expected to be the fastest-growing product segment over the forecast period owing to their cost effectiveness, flexibility, and controlling pain management and wireless remote techniques. Such a device sends mild electrical signals to the spinal cord near painful areas so that it can block the neuropathic pain. It contains a battery, which can get replaced easily through surgical procedures.
Moreover, the increasing number of patients suffering from chronic and neuropathic pain and new product launches by major companies are driving the segment further. For instance, in June 2015, Boston Scientific launched its Precision Novi spinal cord stimulator, which is an Implantable Pulse Generator (IPG). The primary cell spinal cord stimulator implant is designed to enhance patient comfort and address chronic pain, which is one of the primary causes of spinal surgeries.
CRPS segment led the spinal cord stimulation devices market owing to a high number of patients suffering from chronic pain. People suffering from CRPS also experience changes in skin color and temperature. All these changes happen due to abnormal microcirculation caused by the damage to the nerves controlling blood flow and temperature. Some individuals develop CRPS due to injury or trauma, which may involve sprains, fractures, limb immobilization, and soft tissue injury. It also affects the immune system due to inflammatory chemicals found in the tissues. Degenerative disk disease is projected to be the fastest-growing segment over the forecast period owing to increasing cases of degenerative disk disease.
It is mostly an age-related condition that occurs when one or more of the discs between the spinal column and vertebrae deteriorates or break down leading to pain. New product development and technological advancements are also likely to boost segment growth. For instance, Medtronic implantable neurostimulation system is designed to reduce the chronic pain of the limb or of the trunk. It is used for the treatment of failed back syndrome, post laminectomy pain, peripheral causalgia, epidural fibrosis, unsuccessful disk surgery, and CRPS.
North America led the global market in 2018 and is expected to witness substantial growth in the future as well due to increasing cases of chronic pain, failed back syndrome, and CRPS. Moreover, increasing awareness about spinal cord stimulation therapy, the presence of well-established healthcare facilities, and the availability of highly skilled doctors will drive the regional market. Quick adoption of technologically advanced products is also expected to spur market growth.
In addition, increasing reimbursements for innovations in devices, such as wireless remote technique, are positively affecting the market growth in the region. Asia Pacific is expected to witness the highest CAGR due to the increasing number of patients suffering from neuropathic pain after spinal surgeries and chronic pain in the legs, arms, and feet owing to trauma and injuries.
Major companies in the market include Boston Scientific Corp.; Medtronic PLC; NeuroSigma, Inc.; Nevro Corp.; Stimwave LLC; and Synapse Biomedical, Inc. These companies focus on new product development, technological advancements, and growth strategies, such as mergers and acquisitions, to maintain their industry positions.
Report Attribute |
Details |
Market size value in 2020 |
USD 2.1 billion |
Revenue forecast in 2026 |
USD 3.58 billion |
Growth Rate |
CAGR of 8.7% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Russia; China; Japan; India; Australia; South Korea; Singapore; Brazil; Mexico; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Boston Scientific Corporation, St. Jude Medical, Inc, (Abbott), Neurosigma Inc, Nevro Corp, Synapse Biomedical Inc, Medtronic |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global spinal cord stimulation devices market report on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Rechargeable
Non-Rechargeable
Application Outlook (Revenue, USD Million, 2015 - 2026)
Failed Back Syndrome
Complex Regional Pain Syndrome
Degenerative Disk Disease
Unsuccessful Disk Surgery
Others
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
China
Japan
India
Australia
South Korea
Singapore
Latin America
Brazil
Mexico
Argentina
Columbia
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global spinal cord stimulation devices market size was estimated at USD 2.0 billion in 2019 and is expected to reach USD 2.1 billion in 2020.
b. The global spinal cord stimulation devices market is expected to grow at a compound annual growth rate of 8.7% from 2019 to 2026 to reach USD 3.5 billion by 2026.
b. North America dominated the spinal cord stimulation devices market with a share of 30.88% in 2019. This is attributable to the increasing prevalence of chronic pain and neuropathic pain, presence of well-established healthcare facilities in the region, and availability of highly skilled neurologists.
b. Some of the key players operating in the spinal cord stimulation devices market include Boston Scientific Corporation, St. Jude Medical, Inc, (Abbott), Neurosigma Inc, Nevro Corp, Synapse Biomedical Inc, and Medtronic.
b. Key factors that are driving the market growth include increasing incidence of failed back syndrome, availability of medical reimbursements, increase in number of patients suffering from chronic pain, increasing incidence of complex regional pain syndrome.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.